Latest 10-K annual reports

CannaPharmaRx, a Canadian cannabis cultivator, reported a widened net loss of $11.1 million for 2025 and faces substantial doubt about its ability to continue as a going concern.

Vynleads, Inc. reported zero revenue for 2025 and 2024, a widening working capital deficit, and substantial doubt about its ability to continue as a going concern, despite a strategic shift to an AI-enabled subscription platform.

Mainz Biomed slashes legacy cancer programs, sells ColoAlert IP, lines up $6M preferred financing that could exceed 95% dilution, and seeks shareholder approval to rebrand as Quantum Cyber N.V.

Smart Powerr Corp. reported a net loss of $2.9 million for fiscal year 2025, driven by increased operating expenses, while actively transitioning into an energy storage integrated solution provider.

enCore Energy Corp. reported increased uranium extraction and significant regulatory advancements for its U.S. projects in 2025, despite a decrease in revenue and continued negative operating cash flow.

Brainstorm Cell Therapeutics Inc. reports a net loss of $10.3 million for 2025, delisting from Nasdaq, and continues development of NurOwn for ALS despite past FDA setbacks.

Vaso Corporation announced its annual results for 2025, reporting a significant increase in net income driven by strategic divestments and strong professional sales services, despite an impairment charge in its IT segment.

BluSky AI Inc., transitioning to AI data centers, reported a net loss of $4.5 million for 2025 and faces substantial doubt about its ability to continue as a going concern.

Spruce Power Holding Corporation reported a significant reduction in net losses for 2025, driven by revenue growth and operational efficiencies, but faces substantial doubt about its ability to continue as a going concern due to debt maturities.

VSee Health, Inc. reported a 40% revenue increase in 2025 but faces substantial doubt about its ability to continue as a going concern, coupled with Nasdaq minimum bid price non-compliance and material internal control weaknesses.

LanzaTech Global, Inc. reported a reduced net loss in 2025 but disclosed substantial doubt about its ability to continue as a going concern, necessitating significant future financing.

Bimergen Energy, a renewable energy developer, reported increased net losses in 2025 as it advances a 3.6 GW BESS and solar project pipeline and secures significant post-year-end financing.

Direct Digital Holdings reported a significant net loss and revenue decline in 2025, driven by disruptions in its sell-side business, while shifting focus to buy-side and enterprise customers for future growth amidst going concern doubts.

Velo3D reports increased 3D printer and parts revenue in 2025, but faces substantial doubt about its ability to continue as a going concern, necessitating further financing.

CN Healthy Food Tech Group Corp. reports significant revenue and net income growth in 2025, yet faces a Nasdaq trading halt, defaulted promissory notes, and material weaknesses in internal controls.

KULR Technology Group achieved record annual revenues in 2025, driven by new digital asset mining and product sales, despite significant impairment charges and an unrealized loss on Bitcoin holdings.

Skillz Inc. reports a 13% revenue increase to $104.5 million in 2025, driven by its RZR segment, despite a wider net loss of $70.4 million and ongoing litigation.

FG Imperii Acquisition Corp. (FGI) filed its annual report, outlining its blank check company structure, proposed IPO, and financial position as of December 31, 2025, ahead of a planned business combination in the financial services sector.

Reading International, Inc. reported a significant reduction in net losses for 2025, driven by improved operating income and strategic asset sales, while actively managing debt maturities and liquidity.

TAO Synergies Inc. has shifted its core business from biopharmaceutical development to a cryptocurrency treasury strategy focused on Bittensor's TAO token, reporting a significant unrealized loss on digital assets for 2025.

Xsolla SPAC 1, a blank check company, filed its annual 10-K report detailing its recent $204 million IPO and strategic focus on high-growth sectors for its initial business combination.

Nuvve Holding Corp. reported a significant increase in net losses for fiscal year 2025, driven by higher operating expenses and a decline in service revenue, despite strategic acquisitions and capital raising efforts.

Planet Green Holdings Corp. reported a significant increase in net loss and a substantial decline in revenue for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern.

Tailwind 2.0 Acquisition Corp. files its 2025 annual report, detailing its SPAC structure, successful IPO, and strategic focus on energy and compute infrastructure for its initial business combination.

Binah Capital Group, Inc. reported a significant turnaround in 2025, achieving $2.3 million in net income on $187.1 million in revenue, alongside growth in advisory and brokerage assets.

Lyra Therapeutics, a clinical-stage biotech, announced the suspension of its lead drug candidate LYR-210 development, a significant workforce reduction, and its delisting from Nasdaq, as it explores strategic alternatives amidst substantial financial losses.

Tevogen Bio Holdings Inc. reported a net loss of $26.3 million for 2025, alongside positive Phase 1 clinical trial results for TVGN 489 and ongoing development of its ExacTcell technology.

Super League Enterprise, Inc. reports a 30% revenue decrease in Fiscal Year 2025 but significantly improved liquidity through debt-to-equity conversions and a $20 million private placement, while strategically focusing on scalable media solutions.

Free Flow USA Inc. reported a net loss of $192,333 for 2025, a significant decline from the prior year's net income, as it navigates operational changes and seeks new business opportunities.

TuHURA Biosciences reported increased losses and substantial doubt about its ability to continue as a going concern despite advancing its immuno-oncology pipeline and securing recent financing.